Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF ACCOUNTING OFFICER | July 15, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date July 15, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 29,062 |
Ending reported balance
After 2026-09-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-07-15 · Grant · Acquired 279 · Balance 27,697 F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Row 2 · 2026-09-01 · Exercise / conversion · Acquired 3,932 · Balance 31,629 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 2,558 · Balance 34,187 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,362 · Balance 36,549 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Exercise / conversion · Acquired 2,644 · Balance 39,193 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 6 · 2026-09-01 · Tax withholding · Disposed 5,531 · Balance 33,662 Row 7 · 2026-09-03 · Sale · Disposed 4,600 · Balance 29,062 F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,650 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 3,650 · Balance 3,650 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,931 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 2,644 · Balance 7,931 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 4,725 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,362 · Balance 4,725 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 2,557 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 2,558 · Balance 2,557 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 3,932 · Balance 0 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 14,600 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 14,600 · Balance 14,600 F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 4,600 | $80.30 | $369,380.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,062 F3 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 13 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 3,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 12 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,557 Underlying: Class A Ordinary Share · 2,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 11 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,725 Underlying: Class A Ordinary Share · 2,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 10 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,931 Underlying: Class A Ordinary Share · 2,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 14,600 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,600 Underlying: Class A Ordinary Share · 14,600 shares Expires 2036-08-31 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,650 Underlying: Class A Ordinary Share · 3,650 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 5,531 | $79.28 | $438,497.68 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,662 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 15, 2026 Filed Sep 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 279 | $33.50 | $9,346.50 |
DisclosureSEC source: 0001464583-26-000008 · form4-09032026_080913.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,697 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 6,625 | $46.69 | $309,321.25 |
DisclosureSEC source: 0001464583-26-000006 · form4-04132026_080442.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,418 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000004 · form4-04082026_080417.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 3,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,666 | $48.94 | $81,534.04 |
DisclosureSEC source: 0001464583-26-000004 · form4-04082026_080417.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,043 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,932 | $1.00 | $3,932.00 |
DisclosureSEC source: 0001464583-26-000004 · form4-04082026_080417.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,931 Underlying: Class A Ordinary Share · 2,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,725 Underlying: Class A Ordinary Share · 2,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,557 Underlying: Class A Ordinary Share · 2,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 7,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,300 Underlying: Class A Ordinary Share · 73,000 shares Expires not disclosed F5 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F6 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. F6 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,650 Underlying: Class A Ordinary Share · 3,650 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 14,600 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,600 Underlying: Class A Ordinary Share · 14,600 shares Expires 2036-03-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 3,205 | $48.13 | $154,256.65 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,777 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 7,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| January 15, 2026 Filed Apr 3, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 372 | $24.16 | $8,987.52 |
DisclosureSEC source: 0001464583-26-000002 · form4-04032026_080430.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,418 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,787 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · derivative · entry 12 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 12,787 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9,831 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · derivative · entry 11 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 9,831 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9,831 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · derivative · entry 10 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 9,831 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,195 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 6,195 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 791 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 791 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 13,235 | $39.31 | $520,267.85 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,046 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.145 and $39.57. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 37,255 | $38.72 | $1,442,513.60 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,281 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 12,787 | $10.76 | $137,588.12 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,831 | $11.97 | $117,677.07 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,831 | $11.10 | $109,124.10 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,195 | $12.97 | $80,349.15 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 791 | $15.50 | $12,260.50 |
DisclosureSEC source: 0001464583-25-000005 · form4-10222025_091045.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. Read SEC document |
| October 04, 2025 Filed Oct 8, 2025 20:58 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001464583-25-000003 · form4-10082025_081015.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. Read SEC document |
| October 04, 2025 Filed Oct 8, 2025 20:58 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 85 | $38.49 | $3,271.65 |
DisclosureSEC source: 0001464583-25-000003 · form4-10082025_081015.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,101 Read SEC document |
| October 04, 2025 Filed Oct 8, 2025 20:58 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001464583-25-000003 · form4-10082025_081015.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 11,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 15 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 11,000 shares Expires 2029-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F10 · derivative.exercise_date: The option is fully vested and Exercisable. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 11,000 | $34.84 | $383,240.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,011 F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $34.80 and $35.005. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 11,000 | $17.92 | $197,120.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 14 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F9 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 375 | $34.28 | $12,855.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,011 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 13 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,932 Underlying: Class A Ordinary Share · 3,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 12 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,115 Underlying: Class A Ordinary Share · 2,557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 11 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,087 Underlying: Class A Ordinary Share · 2,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.